Shu Yazaki

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Roberto A. Leon‐Ferre, Sarah Flora Jonas, Roberto Salgado et al. · JAMA · 2024 · 199 citations · Full text

Medicine, Immunology, Oncology +15

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy

Shu Yazaki, Tatsunori Shimoi, Masayuki Yoshida et al. · Breast Cancer Research and Treatment · 2022 · 16 citations · Full text

Life Sciences, Immunology, Oncology +16

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer

Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai et al. · Frontiers in Oncology · 2023 · 15 citations · Full text

Medicine, Oncology, Breast Oncology +14

Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study

Shu Yazaki, Jun Hashimoto, Shin Ogita et al. · Anti-Cancer Drugs · 2020 · 14 citations

Medicine, Oncology, Pharmacology +17

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)

Takamichi Yokoe, Sasagu Kurozumi, Kazuki Nozawa et al. · Breast Cancer · 2021 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17